Skip to main content
SpringerLink
Log in

Losartan

In the Reduction of Stroke Risk in Patients with Hypertension and Left Ventricular Hypertrophy

  • Apis Drug Profile
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

▴ Losartan binds selectively to the angiotensin II subtype 1 receptor, blocking the activity of angiotensin II.

▴ Losartan 50–100 mg/day was compared with atenolol 50–100 mg/ day in patients with essential hypertension and left ventricular hypertrophy (LVH) [n = 9193] in the randomized, double-blind Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Two substudies compared these drugs in patients with diabetes mellitus (n = 1195) or isolated systolic hypertension (ISH) [n = 1326].

▴ The target BP (‘140/90mm Hg) was achieved in ≈45% of losartan and atenolol recipients in the LIFE study. Significant regression of LVH occurred with losartan versus atenolol in the LIFE study, as well as in the diabetes mellitus and ISH substudies.

▴ In the LIFE study, although BP reduction was similar for the two treatments, the risk of a cardiovascular event (the composite of cardiovascular death, stroke, and myocardial infarction; primary endpoint), stroke, or new-onset diabetes mellitus was significantly lower with losartan than with atenolol.

▴ Losartan was generally well tolerated in patients with hypertension and LVH in the LIFE study. Significantly fewer losartan than atenolol recipients discontinued treatment because of adverse events, drug-related adverse events, or serious, drug-related adverse events.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

Notes

  1. Use of tradenames is for product identification purposes only and does not imply endorsement.

References

  1. Guidelines Subcommittee of the WHO-ISH. 1999 World Health Organisation -International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999 Feb; 17: 151–83

    Google Scholar 

  2. Davis R, Benfield P. Management of primary hypertension: the potential role of losartan. Dis Manage Health Outcomes 1997 Apr; 1 (4): 210–22

    Article  Google Scholar 

  3. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists and other blood-pressure-lowering drugs; results of prospectively designed overviews of randomised trials. Blood Pressure Treatment Trialists’ Collaboration. Lancet 2000; 356: 1955–64

    Article  PubMed  CAS  Google Scholar 

  4. Dalhöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar 23; 359 (9311): 995–1003

    Article  Google Scholar 

  5. Koren M, Devereux R, Casale P, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114: 345–52

    PubMed  CAS  Google Scholar 

  6. Verdecchia P, Schillaci G. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97: 48–54

    Article  PubMed  CAS  Google Scholar 

  7. Devereux RB, Roman MJ, Palmieri V, et al. Left ventricular wall stresses and wall stress-mass-heart rate products in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention For Endpoint reduction in hypertension. J Hypertens 2000 Aug; 18 (8): 1129–38

    Article  PubMed  CAS  Google Scholar 

  8. Muiesan M, Salvetti M, Rizzonis D, et al. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995; 13: 1091–5

    Article  PubMed  CAS  Google Scholar 

  9. Mathew J, Sleight P, Lonn E, et al. Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Heart Outcomes Prevention Evaluation (HOPE) Investigators. Circulation 2001; 104: 1615–21

    Article  PubMed  CAS  Google Scholar 

  10. Merck & Co., Inc. COZAAR® (Losartan Potassium Tablets) PI [online]. Available from URL: http://www.cozaar.com/cozaar/shared/documents/pi_cozaar.pdf [Accessed 2003 Jul 10]

  11. Merck Sharp & Dohme. UK prescribing information [online]. Available from URL: http://emc.medicines.org.uk/ [Accessed 2003 Sep 3]

  12. Merck & Co., Inc. FDA approves COZAAR® as the first and only hypertension medicine to help prevent stroke in patients with hypertension and left ventricular hypertrophy [media release]. Available from URL: http://www.merck.com/ [Accessed 2003 Aug 6]

  13. Timmermans P, Wong P, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993 Jun; 45: 205–51

    PubMed  CAS  Google Scholar 

  14. Chiu A, McCall D, Aldrich P, et al. [3H]DUP753, a highly potent and specific radioligand for the angiotensin II-1 receptor subtype. Biochem Biophys Res Commun 1990 Nov 15; 172: 1195–202

    Article  PubMed  CAS  Google Scholar 

  15. Cody R. The clinical potential of renin inhibitors and angiotensin antagonists. Drugs 1994 Apr; 47: 586–98

    Article  PubMed  CAS  Google Scholar 

  16. Christen Y, Waeber B, Nussberger J. Dose-response relationships following oral administration of DuP753 to normal humans. Am J Hypertens 1991 Apr; 4 Suppl.: 350S–3S

    PubMed  CAS  Google Scholar 

  17. Simpson KL, McClellan KJ. Losartan: a review of its use, with special focus on elderly patients. Drugs Aging 2000 Mar; 16 (3): 227–50

    Article  PubMed  CAS  Google Scholar 

  18. Goa K, Wagstaff A. Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996 May; 51 (5): 820–45

    Article  PubMed  CAS  Google Scholar 

  19. Lindholm LH, Ibsen H, Dalhöf B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359 (9311): 1004–10

    Article  PubMed  CAS  Google Scholar 

  20. Kjeldsen SE, Dalhöf B., Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002 Sep 25; 288 (12): 1491–8

    Article  PubMed  CAS  Google Scholar 

  21. Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol. The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study. Circulation 2003 Jul 28; 108: 684–90

    Article  PubMed  CAS  Google Scholar 

  22. Burrell L, Johnston C. Angiotensin II receptor antagonists: potential in elderly patients with cardiovascular disease. Drugs Aging 1997 Jun; 10: 421–34

    Article  PubMed  CAS  Google Scholar 

  23. Burnier M, Rutschmann B, Nussberger J, et al. Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects. Hypertension 1993 Sep; 22: 339–47

    Article  PubMed  CAS  Google Scholar 

  24. Azizi M, Chatellier G, Thanh-Tam G, et al. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium depleted normotensives. Circulation 1995; 92: 825–34

    Article  PubMed  CAS  Google Scholar 

  25. Goldberg M, Tanaka W, Barchowsky A, et al. Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers. Hypertension 1993 May; 21: 704–13

    Article  PubMed  CAS  Google Scholar 

  26. Tsunoda K, Abe K, Hagino T, et al. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993 Jan; 6: 28–32

    PubMed  CAS  Google Scholar 

  27. Erly C, Bader B, Scheu M, et al. Renal hemodynamics in essential hypertensives treated with losartan. Clin Nephral 1995 Jan; 43 Suppl. 1: S8–11

    Google Scholar 

  28. Lo M-W, Golberg M, McCrea J, et al. Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans. Clin Pharmacol Ther 1995 Dec; 58: 641–9

    Article  PubMed  CAS  Google Scholar 

  29. Dalhöf B, Devereux R, Julius S, et al. Characteristics of 9194 patients with left ventricular hypertrophy in the LIFE study. Hypertension 1998 Dec; 32: 989–97

    Article  Google Scholar 

  30. Kjeldsen SE, Dahlof B, Devereux RB, et al. Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy: the LIFE study. Am J Hypertens 2000 Aug; 13 (8): 899–906

    Article  PubMed  CAS  Google Scholar 

  31. Lindholm LH, Ibsen H, Borch-Johnsen K, et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002 Sep; 20 (9): 1879–86

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Inc., 770 Township Line Road, Suite 300, Yardley, PA, 19067, USA

    John Waugh & Gillian M. Keating

Authors
  1. John Waugh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gillian M. Keating
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John Waugh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Waugh, J., Keating, G.M. Losartan. Am J Cordiovosc Drugs 3, 371–377 (2003). https://doi.org/10.2165/00129784-200303050-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00129784-200303050-00008

Keywords

Search

Navigation